Mirum Pharmaceuticals (MIRM) EBITDA Margin (2021 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly EBITDA Margin of 493.78% for Q1 2026, down 48017.0% year-over-year from N/an in Q1 2025, and down 16002.39% quarter-over-quarter from 3.07% in Q4 2025.
Powered by 
Analysis
Mirum Pharmaceuticals (MIRM) EBITDA Margin (2021 - 2026) Analysis & Trends
Mirum Pharmaceuticals' EBITDA Margin history runs 6 years deep, the most recent figure standing at 493.78% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 48017.0% year-over-year to 493.78%; the TTM figure through Mar 2026 stood at 139.82% (down 11969.0% YoY), while the FY2025 annual figure was 4.25%, up 2176.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 493.78%, down from 3.07% in the prior quarter.
- The five-year high for EBITDA Margin was 1.96% in Q3 2025, with the low at 493.78% in Q1 2026.
- The 5-year median for EBITDA Margin is 46.85% (2023), against an average of 94.21%.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin surged 132994 bps in 2022, then sank 48017 bps in 2026.
- Mirum Pharmaceuticals' EBITDA Margin stood at 122.41% in 2022, then soared by 62 bps to 46.85% in 2023, then surged by 48 bps to 24.36% in 2024, then surged by 87 bps to 3.07% in 2025, then sank by 16002 bps to 493.78% in 2026.
- Business Quant data shows MIRM's EBITDA Margin at 493.78% in Q1 2026, 3.07% in Q4 2025, and 1.96% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Mirum Pharmaceuticals | 6.40 Bn | 5.96 Bn | 145.90 Mn | -24.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.14% |
| Mar 31, 2026 | -493.78% |
| Dec 31, 2025 | -3.07% |
| Sep 30, 2025 | 1.96% |
| Jun 30, 2025 | -3.90% |
| Mar 31, 2025 | -13.61% |
| Dec 31, 2024 | -24.36% |
| Sep 30, 2024 | -14.03% |
| Jun 30, 2024 | -31.12% |
| Mar 31, 2024 | -38.24% |
| Dec 31, 2023 | -46.85% |
| Sep 30, 2023 | -52.69% |
| Jun 30, 2023 | -64.73% |
| Mar 31, 2023 | -85.92% |
| Dec 31, 2022 | -122.41% |
| Sep 30, 2022 | -175.09% |
| Jun 30, 2022 | -179.83% |
| Mar 31, 2022 | -253.92% |
| Dec 31, 2021 | -1,452.36% |
| Sep 30, 2021 | -856.48% |